Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α_West China Medical Journal

Authors：

Department of Infectious Diseases, the First People’s Hospital of Yibin City, Yibin Sichuan 644000, China;

Corresponding author：

Keywords：

α干扰素; HBeAg(+); 慢性乙型肝炎; 病毒学; 血清学

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:观察α干扰素治疗HBeAg(+)慢性乙型肝炎患者过程中病毒学及血清学动态变化情况,通过早期疗效预测终末疗效。方法:观察144例HBeAg(+)慢性乙型肝炎患者经α干扰素治疗24WK及随访24WK 过程中HBV-DNA以及HBeAg变化情况.结果:经α干扰素治疗12、24、48WK时,HBV-DNA下降到可检测值以下病例数分别为32、32、31例;同期HBeAg发生血清转换病例数分别为16、17、21例。结论:干扰素治疗12WK时患者病毒学及血清学结果可早期预测终末疗效。

Citation： ZHENG Yongli.. Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α. West China Medical Journal, 2009, 24(9): 2334-2335. doi: Copy

1.	INADA M, YOKOSUKA O. Current antiviral therapies for chronic hepatitis B[J]. Hepatol Res, 2008, 38(6):535-42.
2.	PLANAS R, MORILLAS R M. Treatment of hepatitis B virus infection: present and future[J]. Gastroenterol Hepatol,2008, 31(6):349-355.
3.	RAMOSBELLO D, RAMOSNIEMBRO F. A review of interferons: fifty years later (19572007)[J]. Gac Med Mex,2008,144(1):55-65.
4.	THOMAS H C, KARAYIANNIS P, BROOK G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon[J]. J Hepatol,1991;13 Suppl 1:S4-7.
5.	RUIZMORENO M, CAMPS T, JIMENEZ J, et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B[J].J Hepatol,1995 May;22(5):540-4.
6.	TER BORG M J, VAN ZONNEVELD M, ZEUZEM S, et al. Patterns of viral decline during PEGinterferon α2b therapy in HBeAgpositive chronic hepatitis B: relation to treatment response[J]. Hepatology, 2006 Sep;44(3):721-7.
7.	VAN DER EIJK A A, NIESTERS H G, HANSEN B E, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBeantigen positive hepatitis B patients treated with interferonα[J]. J Viral Hepat, 2006 Feb;13(2):96-103.

1. INADA M, YOKOSUKA O. Current antiviral therapies for chronic hepatitis B[J]. Hepatol Res, 2008, 38(6):535-42.
2. PLANAS R, MORILLAS R M. Treatment of hepatitis B virus infection: present and future[J]. Gastroenterol Hepatol,2008, 31(6):349-355.
3. RAMOSBELLO D, RAMOSNIEMBRO F. A review of interferons: fifty years later (19572007)[J]. Gac Med Mex,2008,144(1):55-65.
4. THOMAS H C, KARAYIANNIS P, BROOK G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon[J]. J Hepatol,1991;13 Suppl 1:S4-7.
5. RUIZMORENO M, CAMPS T, JIMENEZ J, et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B[J].J Hepatol,1995 May;22(5):540-4.
6. TER BORG M J, VAN ZONNEVELD M, ZEUZEM S, et al. Patterns of viral decline during PEGinterferon α2b therapy in HBeAgpositive chronic hepatitis B: relation to treatment response[J]. Hepatology, 2006 Sep;44(3):721-7.
7. VAN DER EIJK A A, NIESTERS H G, HANSEN B E, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBeantigen positive hepatitis B patients treated with interferonα[J]. J Viral Hepat, 2006 Feb;13(2):96-103.

West China Medical Journal

Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α

Abstract Full text Figures/Tables Video References Cited by

Format

Content